TG Therapeutics, Inc. $TGTX Stock: Pictet Asset Management Holding SA Trims Position

Pictet Asset Management Holding SA lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 10.3% during the third quarter, Holdings Channel reports. The fund owned 1,602,568 shares of the biopharmaceutical company’s stock after selling 183,383 shares during the quarter. Pictet Asset Management Holding SA’s holdings in TG Therapeutics were worth $89,391,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Farther Finance Advisors LLC raised its stake in TG Therapeutics by 45.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 993 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 312 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares during the last quarter. Signaturefd LLC boosted its stake in shares of TG Therapeutics by 193.5% during the 3rd quarter. Signaturefd LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 720 shares during the last quarter. Harbor Investment Advisory LLC purchased a new stake in shares of TG Therapeutics during the second quarter worth about $96,000. Finally, Pingora Partners LLC purchased a new stake in shares of TG Therapeutics during the second quarter worth about $121,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Up 5.9%

Shares of TGTX stock opened at $63.38 on Tuesday. The firm has a market cap of $9.70 billion, a P/E ratio of 23.13, a PEG ratio of 2.60 and a beta of 1.89. TG Therapeutics, Inc. has a 1-year low of $26.76 and a 1-year high of $63.60. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. The firm’s 50-day simple moving average is $55.99 and its 200-day simple moving average is $44.66.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.02). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The company had revenue of $259.94 million during the quarter, compared to analyst estimates of $245.47 million. During the same period in the prior year, the business posted $2.43 earnings per share. TG Therapeutics’s revenue was up 60.8% on a year-over-year basis. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on TGTX. Weiss Ratings raised shares of TG Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, November 4th. B. Riley Financial raised their target price on shares of TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. JPMorgan Chase & Co. lifted their target price on shares of TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a report on Tuesday, September 1st. Finally, Zacks Research raised TG Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $63.00.

Key Stories Impacting TG Therapeutics

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: Third-quarter revenue was $259.9 million, up 60.8% year over year and above estimates of about $245.5 million. TG Therapeutics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 revenue outlook to $1.0 billion, ahead of the roughly $961 million consensus. CEO Michael Weiss also said global revenue could exceed $1 billion, with BRIUMVI driving growth. TG Therapeutics CEO sees global revenue exceeding $1B in 2026
• Neutral Sentiment: EPS was $0.35. That topped Zacks’ $0.28 estimate, but was below other reported consensus figures around $0.37; earnings were also lower than the $2.43 reported a year earlier. TG Therapeutics beats Q3 earnings and revenue estimates

Insiders Place Their Bets

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the transaction, the director owned 168,640 shares of the company’s stock, valued at $9,268,454.40. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.87% of the stock is currently owned by corporate insiders.

TG Therapeutics Profile

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases, including autoimmune disorders and blood cancers. Its research has centered on therapies that target B cells, a type of immune cell involved in these conditions.

The company’s marketed product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved in the United States to treat adults with relapsing forms of multiple sclerosis. TG Therapeutics also has investigated other drug candidates and combinations for immune-related and hematologic diseases.

Headquartered in New York, TG Therapeutics serves patients in the United States and has expanded BRIUMVI’s availability into international markets, including Europe.